Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity
A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 5056 participants.
Also called NCT07037459
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 5,056 participants
- Sponsor
- Registry
-
NCT07037459
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States, Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Czechia, Denmark, Finland, France, Germany, Greece, Hong Kong SAR China, Hungary, Italy, Japan, Mexico, Netherlands, Poland, Portugal, Puerto Rico, Romania, Slovakia, South Korea, Spain, Sweden, Switzerland, Taiwan, Türkiye, United Kingdom
- Registry status
- Recruiting
Technical summary
Registry record NCT07037459. Randomized; double masking; primary purpose treatment. Start 2025-06-25 (actual); primary completion 2028-06-30 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity
- Acronym
- MARITIME-HF
- Condition
- Heart Failure With Mildly Reduced Ejection Fraction
- Condition
- Obesity
- Intervention (Drug)
- Maridebart cafraglutide
- Intervention (Drug)
- Placebo
- Lead sponsor
- Amgen
Record details
- Record id
cardio:ct-nct07037459- Content hash
eedddb95a87e887467e61a930d9f2114d7b49992ea2f3006878938a8b08620fa